Metallochaperones are needed for Mycobacterium tuberculosis and Escherichia coli nicotinamidase-pyrazinamidase activity, and contribute to pyrazinamide resistance in tuberculosis.
Background: Mycobacterium tuberculosis nicotinamidase/pyrazinamidase (PZAse) is a metalloenzyme that catalyzes conversion of nicotinamide/pyrazinamide to nicotinic acid/pyrazinoic acid. This study investigated whether a metallochaperone is required for optimal PZAse activity.Methods: M. tuberculosis and E.coli PZAses (PZAse-MT and PZAse-EC respectively) were inactivated by metal depletion (giving PZAse-MT-Apo and PZAse-EC-Apo). Reactivation with E.coli metallochaperone ZnuA or Rv2059 (M. tuberculosis analog) was measured. This was repeated following proteolytic and thermal treatment of ZnuA and Rv2059. The CDC1551 M. tuberculosis reference strain was knocked-out for the Rv2059 coding gene, and was measured PZA susceptibility and POA efflux rate.Results: 200 μM ZnuA achieved 65% PZAse-EC-Apo reactivation. 1 μM Rv2059 and 1 μM ZnuA achieved 69% and 34.3% PZAse-MT-Apo reactivation respectively. Proteolytic treatment of ZnuA and Rv2059, and application of three thermal shocks (but not one) to ZnuA, significantly reduced capacity to reactivate PZAse-MT-Apo. M. tuberculosis Rv2059 knock-out strain was Wayne positive, susceptible to PZA, and did not have a significantly different POA efflux rate compared to the reference strain, although a trend of a lower efflux rate was observed after knock-out.Conclusion: The metallochaperone Rv2059 restores activity of metal-depleted PZAse in vitro Although the importance of Rv2059 in vitro, it seems to have a lesser effect in PZA susceptibility in vivo. It may be important to mechanisms of action and of resistance to pyrazinamide in M. tuberculosis Further studies are needed for confirmation.IMPORTANCE Tuberculosis is an infectious disease caused by the bacterium Mycobacterium tuberculosis and remains one of the major causes of disease and death worldwide. Pyrazinamide is a key drug used in the treatment of tuberculosis, yet its mechanism of action is not fully understood, and testing strains of Mycobacterium tuberculosis for pyrazinamide resistance is not well done with the tools that are presently available. The significance of this research is that a metallochaperone-like protein may be crucial to pyrazinamide's mechanisms of action and of resistance. This may support the development of improved tools to detect pyrazinamide resistance. It would have significant implications on the clinical management of patients with tuberculosis: drug regimens that are appropriately tailored to a patient's individual strain's resistance profile lead to better clinical outcomes, reduced onwards transmission of infection, and a reduction in the development of resistant strains which are more challenging and expensive to treat.